Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company
Independent directors’ opinions on the seventh interim meeting of the second board of directors
Independent opinions on relevant matters
In accordance with the company law of the people’s Republic of China (hereinafter referred to as the “company law”), the securities law of the people’s Republic of China, the Listing Rules of the Shanghai Stock Exchange on the science and innovation board, and the Listing Rules of the stock exchange of Hong Kong Limited As the independent directors of Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company (hereinafter referred to as “the company”), we are the independent directors of Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company (hereinafter referred to as “the company”) and, Based on the independent, prudent and objective position and careful analysis, we hereby express the following independent opinions on the proposal on repurchase of A-Shares of the company by centralized bidding transaction considered at the seventh extraordinary meeting of the second board of directors of the company:
1. This share repurchase of the company complies with the relevant provisions of the company law and other laws and regulations, normative documents and the articles of association. The voting procedures of the board meeting to consider this matter comply with the relevant laws, regulations and the articles of association.
2. The shares repurchased this time are intended to be used for employee stock ownership plan or equity incentive, which is conducive to further improving the company’s long-term incentive mechanism, fully mobilizing the work enthusiasm of the company’s managers and core team, and promoting the healthy and long-term development of the company.
3. The capital of the company’s share repurchase this time comes from the company’s own funds, which will not have a significant impact on the company’s operation, finance and future development. After the repurchase, the company’s equity distribution meets the conditions of a listed company and will not affect the company’s listing status.
4. This repurchase is implemented in the form of centralized bidding transaction, and there is no situation that damages the interests of the company and all shareholders, especially minority shareholders.
In conclusion, the company’s share repurchase is legal and compliant, which is conducive to promoting the long-term development of the company. There is no situation that damages the interests of the company and all shareholders, especially minority shareholders. We agree to the share repurchase plan. Independent directors: Wei Shaokun, Xin Zhu, GUI Shuifa, Liu Jianzhong January 23, 2022
